See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: Feb. 13, 2007

Renal Cell Cancer Depression Schizophrenia and Schizoaffective Disorders

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Renal Cell Cancer

This trial will evaluate whether sunitinib malate, administered on a 4/2 schedule (4 weeks on treatment, 2 weeks off treatment cycle) is any better at delaying progression of renal cell cancer than sunitinib malate given on a continuous dosing schedule. Volunteers may be included who have advanced renal cell carcinoma, clear cell histology or with a component of clear cell, and no prior therapy for advanced disease. Additional criteria may apply.

The research sites are located across the United States.

More information

Please see



This 16-week trial, including 12 clinic visits, will evaluate a new medication to treat depression. Women 18-65 may qualify who have a current depressive episode of at least three months, and have no history of other psychological or major medical conditions.

The research site is in Wheat Ridge, Colo.

More information

Please see


Schizophrenia and Schizoaffective Disorders

You may qualify for this study if you have been diagnosed with schizophrenia and your current medication is not helping. Candidates 18-65 who have been diagnosed with schizophrenia or schizoaffective disorder may be eligible. To participate, you must be willing to switch from your current therapy to the FDA-approved study drug.

The research site is in New Britain, Conn.

More information

Please see


Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.